Tivozanib

BNF:
Not listed
Status:
Red
Decision Date:
April 2018
 

Comments

RED 1,2,3:NICE TA512: for treating advanced renal cell carcinoma.

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again